Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURING: Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis
2018-004611-50Phase 3Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nephrosis and focal segmental glomerulosclerosis (FSGS) comparing Rituximab with Placebo (2 arms). Primary endpoint: Time to relapse of nephrotic syndrome. Status: unknown.
02
Drugs
rituximab
03
Conditions
nephrosisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2018-004611-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004611-50.